BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29193012)

  • 1. Advances in targeted therapy for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2018 Feb; 180(4):484-500. PubMed ID: 29193012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on targeted therapies for acute myeloid leukaemia.
    Kayser S; Levis MJ
    Br J Haematol; 2022 Jan; 196(2):316-328. PubMed ID: 34350585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    McMahon CM; Perl AE
    Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly targeted therapy in acute myeloid leukemia.
    Gill H; Leung AY; Kwong YL
    Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rocky road to personalized medicine in acute myeloid leukaemia.
    Brinda B; Khan I; Parkin B; Konig H
    J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
    Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
    Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
    Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Future of Targeting FLT3 Activation in AML.
    Leick MB; Levis MJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Treatment Paradigms in Acute Myeloid Leukemia.
    Khanal N; Upadhyay Banskota S; Bhatt VR
    Clin Pharmacol Ther; 2020 Sep; 108(3):506-514. PubMed ID: 32572947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
    Beyar-Katz O; Gill S
    Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the
    Amaya ML; Pollyea DA
    Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Bewersdorf JP; Stahl M; Zeidan AM
    Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH Inhibitors in AML-Promise and Pitfalls.
    McMurry H; Fletcher L; Traer E
    Curr Hematol Malig Rep; 2021 Apr; 16(2):207-217. PubMed ID: 33939107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.